GlassScriptPhysician profile
Lonnie D Miller
NPI 1871762971
$822.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2021: $30.47 · 2022: $356 · 2024: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.68 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $194.54 | 2019-2022 | |
| Janssen Biotech, INC. | $86.80 | 2022-2024 | Talvey, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $85.29 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $79.29 | 2022-2024 | Libtayo |
| Celgene Corporation | $65.93 | 2022-2024 | Reblozyl |
| Abbvie INC. | $41.29 | 2024 | |
| Incyte Corporation | $37.98 | 2024 | Monjuvi, Pemazyre, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $37.95 | 2022 | |
| Pfizer INC. | $37.73 | 2019-2024 | |
| Genzyme Corporation | $35.64 | 2024 | |
| Genentech USA, INC. | $33.13 | 2019-2024 | Columvi, Lunsumio, Polivy |
| Sirtex Medical INC | $26.03 | 2019 | |
| Eisai INC. | $18.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.01 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $13.61 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lonnie Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.